[Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation in Treatment of Intermediate Risk Acute Myeloid Leukemia with Negative for FLT3-ITD, NPM1 or Biallelic CEBPA Mutation].

To compare the efficacy of haploidentical hematopoietic stem cell transplantation (hi-HSCT) HLA-matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT) and post-remission chemotherapy (PR-CT) in treatment of intermediate risk acute myeloid leukemia with negative for FLT3-ITD, NPM1 or biallelic CEBPA mutation. The clinical data of patients with intermediate risk NPM1 The overall survival rate of the patients treated with PR-CT, MSD-HSCT or hi-HSCT was 63.7%, 71.7%, 75.5%, respectively (P＜0.05); the disease-free survival (DFS) rate was 52.8%, 67.1%, 71.3% respectively (P＜0.001); the cumulative incidence of relapse was 24.7%, 16.9%, 14.4% respectively (P＜0.05); the non-relapse mortality was 26.2%, 17.3%, 14.4% reapectively (P＞0.05). The analysis of transplantation, related adverse events showed that II-IV grade of aGVHD in the MSD-HSCT group and hi-HSCT group was 48.9% and 45.6% respectively (P＞0.05); the extensive cGVHD event was 21.6% and 8.8% (P＜0.05) respectively. The efficiency of hi-HSCT and MSD-HSCT is superior to that of PR-CT for treatment of patients with intermediate risk NPM1 单倍体相合造血干细胞移植治疗中危NPM1 探讨三阴性（NPM1 回顾性分析了2009年10月至2016年5月苏州大学附属第一医院血液科收治的268名中危NPM1 化疗组、同胞全相合造血干细胞移植组及单倍体相合造血干细胞移植组的2年总体生存（OS）率分别为63.7%、71.7%和75.5%（P＜0.05）；2年无复发生存（RFS）率分别为52.8%、67.1%和71. 3%（P＜0.001）；累积复发率（CIR）分别为24.7%、16.9% 和14.4%（P＜0.05）；非复发死亡率（NRM）分别为26.2%、17.3%、14.4%（P＞0.05）。移植相关不良事件分析显示，MSD-HSCT组与haploidentical-HSCT组II-IV度aGVHD分别为48.9%和45.6%（P＞0.05）；广泛cGVHD分别为21.6%和8.8%（P＜0.05）. 中危NPM1